Diagnosis of Helicobacter Pylori

Helicobacter pylori is an extremely pervasive bacterium that infects up to 70-90% of individuals in developing countries. H. pylori infection is the principal cause of peptic ulcer disease and the primary risk factor for gastric carcinoma; ~15% of patients with long-term infection will develop one or the other sequel.

The H. pylori Stool Antigen (HpSAg) test directly detects antigens present only during active H. pylori infection. Efficacy of eradication can, therefore, be assessed by testing for active infection before and after treatment. In addition, the HpSAg assay is the only FDA-approved test that can monitor the effectiveness of antibiotic therapy during the 14 days of treatment.

Clinical Utility:The only FDA-approved test for all of the following:

 Detection of active infection.
Monitoring effectiveness of therapy during treatment
Confirmation of antibiotic cure (eradication)

Differentiates between active and latent infection as serology only detects previous exposure.
Relative sensitivity = 95.6%; Relative specificity = 94.7%.
HpSAg identifies 95% of persistent infection cases 7 days post-treatment.

Alfa Laboratory as a comprehensive reference laboratory is offering a complete line of H. pylori tests providing extensive experience and Knowledge for this disease:

H. Pylori Stool Antigen.
H. Pylori Serology (Qualitative and Quantitative).
Urea Breath Test.
Biopsy for H. Pylori.